Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.

doi:10.1111/cas.15171

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.

Cancer science - 1 Jan 2022

Takahashi Toshiaki, Sakai Kazuko, Kenmotsu Hirotsugu, Yoh Kiyotaka, Daga Haruko, Ohira Tatsuo, Ueno Tsuyoshi, Aoki Tadashi, Hayashi Hidetoshi, Yamazaki Koji, Hosomi Yukio, Chen-Yoshikawa Toyofumi F, Okumura Norihito, Takiguchi Yuichi, Sekine Akimasa, Haruki Tomohiro, Yamamoto Hiromasa, Sato Yuki, Akamatsu Hiroaki, Seto Takashi, Saeki Sho, Sugio Kenji, Nishio Makoto, Inokawa Hidetoshi, Yamamoto Nobuyuki, Nishio Kazuto, Tsuboi Masahiro

Abstract excerpt

The mutation status of tumor tissue DNA (n = 389) of resected stage II-III non-squamous non-small-cell lung cancer (Ns-NSCLC) was analyzed using targeted deep sequencing as an exploratory biomarker study (JIPANG-TR) for the JIPANG study, a randomized phase III study of pemetrexed/cisplatin (Pem/Cis) vs vinorelbine/cisplatin (Vnr/Cis). The TP53 mutation, common EGFR mutations (exon 19 deletion and L858R), and KRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Chemotherapy, Adjuvant

Share to Cisplatin

Share to Pemetrexed

Share to Precision Medicine

Share to Survival Analysis

Share to Vinorelbine

Source

Open in PubMed Open full text

Identifiers

PMID: 34689382
DOI: 10.1111/cas.15171
PMCID: PMC8748214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.PMID 34689382Read ↗

Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).Semantic proximity Read ↗

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.Semantic proximity Read ↗

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancerSemantic proximity Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

<i>KRAS</i>mutations impact clinical outcome in metastatic non-small cell lung cancerSemantic proximity Read ↗

EGFR mutations as a predictive marker of cytotoxic chemotherapy.Semantic proximity Read ↗

Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer: The JIPANG Study Protocol.Semantic proximity Read ↗

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma.Semantic proximity Read ↗

Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.Semantic proximity Read ↗

Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy OutcomesSemantic proximity Read ↗

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.